Metformin "sandoz"

Active Ingredient:: Metformin Hydrochloride
Origin:: EU

Metformin "sandoz" (Metformin Hydrochloride)

Q: What is Metformin sandoz used for?

Metformin sandoz is a biguanide oral tablet used to improve blood glucose control in adults with type 2 diabetes mellitus. It lowers hepatic glucose production and increases peripheral insulin sensitivity, helping patients achieve target glycemic levels when combined with diet and exercise.

Q: How does Metformin work in the body?

Metformin primarily inhibits mitochondrial complex I, which reduces the liver’s production of glucose. It also activates AMP‑activated protein kinase (AMPK), promoting glucose uptake in muscle and fat cells and improving insulin sensitivity without stimulating insulin secretion.

Q: What is the usual dose of Metformin sandoz?

The exact dose of Metformin sandoz is determined by the prescribing clinician based on the individual’s renal function, glycemic targets, and tolerability. Dosage adjustments are made during treatment to balance efficacy and side‑effect risk.

Q: Is Metformin sandoz safe during pregnancy or breastfeeding?

Metformin sandoz should be used in pregnancy or while breastfeeding only if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers evaluate each case individually, and alternative therapies may be considered.

Q: How do I order Metformin sandoz from GNH India?

To order Metformin sandoz, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Metformin compare with other antidiabetic drugs?

Metformin belongs to the biguanide class and is often first‑line therapy because it does not cause weight gain and has a low risk of hypoglycemia compared with sulfonylureas or insulin. Unlike newer agents such as GLP‑1 receptor agonists, it is inexpensive and has a well‑established safety profile.

Q: What are the recommended storage conditions for Metformin sandoz?

Metformin sandoz tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Q: How is Metformin sandoz administered?

Metformin sandoz is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water; they are not intended for crushing, chewing, or dissolving unless specifically instructed by a healthcare professional.

Q: What are the most serious risks associated with Metformin sandoz?

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or after exposure to iodinated contrast. Prompt medical attention is required if symptoms such as unexplained fatigue, muscle pain, or rapid breathing develop.

Q: Who should not use Metformin sandoz?

Metformin sandoz is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in patients who have experienced lactic acidosis while on metformin therapy.

Metformin, the active ingredient in Metformin sandoz, is a biguanide presented as an oral tablet for oral use. It is employed to lower elevated blood glucose levels in adults with type 2 diabetes mellitus, improving glycemic control when used alongside diet and exercise.

GNH India supplies Metformin sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for bulk and unit‑dose requirements across multiple regulatory markets.

Manufacturer / TM Owner

Sandoz A/S

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformin is indicated for the management of disorders related to impaired glucose regulation, primarily within the type 2 diabetes mellitus pathway.
Type 2 diabetes mellitus: improves glycemic control by reducing hepatic glucose production and enhancing peripheral insulin sensitivity.
Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes by modestly lowering fasting glucose levels.
Gestational diabetes (when benefits outweigh risks): may be used under specialist supervision to achieve glycemic targets during pregnancy.

How It Works

Metformin acts primarily by inhibiting mitochondrial respiratory-chain complex I, which reduces hepatic gluconeogenesis and decreases hepatic glucose output. It also increases peripheral glucose uptake by activating AMP‑activated protein kinase (AMPK), thereby enhancing insulin‑mediated glucose utilization in muscle and adipose tissue. The combined actions improve overall glycemic control without stimulating insulin secretion.

Side Effects

Metformin is generally well tolerated, but a range of adverse reactions can occur.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite.
Diarrhea: frequent loose stools, especially during dose titration.
Metallic taste: transient alteration in taste perception.
Flatulence: increased intestinal gas.
Vitamin B12 deficiency: reduced absorption with long‑term use.

Serious or Rare Side Effects

Lactic acidosis: a rare but life‑threatening accumulation of lactate.
Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
Hepatic dysfunction: elevated liver enzymes or hepatitis.
Hypoglycemia: usually when combined with other glucose‑lowering agents.
Pancreatitis: inflammation of the pancreas reported in isolated cases.

Precautions & Warnings

Metformin should be used with careful clinical monitoring and patient education.

Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²).
Hepatic function monitoring: caution in patients with liver disease due to lactic acidosis risk.
Lactic acidosis risk: discontinue before radiologic procedures using iodinated contrast.
Pregnancy and breastfeeding: use only if potential benefit justifies potential risk.
Contraindications: avoid in patients with known hypersensitivity to metformin.
Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Avoid Interactions

Metformin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis.
Cimetidine: may increase metformin plasma concentrations.
Alcohol excess: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may mask hypoglycemia symptoms.
Diuretics (especially thiazides): can impair renal clearance of metformin.
ACE inhibitors/ARBs: monitor renal function and potassium levels.
NSAIDs: may reduce renal perfusion, increasing metformin exposure.
Digoxin: potential for altered plasma levels when combined with metformin.

Frequently Asked Questions

Metformin sandoz is a biguanide oral tablet used to improve blood glucose control in adults with type 2 diabetes mellitus. It lowers hepatic glucose production and increases peripheral insulin sensitivity, helping patients achieve target glycemic levels when combined with diet and exercise.

Metformin primarily inhibits mitochondrial complex I, which reduces the liver’s production of glucose. It also activates AMP‑activated protein kinase (AMPK), promoting glucose uptake in muscle and fat cells and improving insulin sensitivity without stimulating insulin secretion.

The exact dose of Metformin sandoz is determined by the prescribing clinician based on the individual’s renal function, glycemic targets, and tolerability. Dosage adjustments are made during treatment to balance efficacy and side‑effect risk.

Metformin sandoz should be used in pregnancy or while breastfeeding only if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers evaluate each case individually, and alternative therapies may be considered.

To order Metformin sandoz, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformin belongs to the biguanide class and is often first‑line therapy because it does not cause weight gain and has a low risk of hypoglycemia compared with sulfonylureas or insulin. Unlike newer agents such as GLP‑1 receptor agonists, it is inexpensive and has a well‑established safety profile.

Metformin sandoz tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Metformin sandoz is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water; they are not intended for crushing, chewing, or dissolving unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or after exposure to iodinated contrast. Prompt medical attention is required if symptoms such as unexplained fatigue, muscle pain, or rapid breathing develop.

Metformin sandoz is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in patients who have experienced lactic acidosis while on metformin therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 05 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.